Defined media for pluripotent stem cell culture

• US 20070010011A1
• Filed: 05/17/2006
• Published: 01/11/2007
• Est. Priority Date: 12/31/2003
• Status: Abandoned Application

• Current Assignee: The Burnham Institute
• Original Assignee: The Burnham Institute
• Inventors: Snyder, Evan, Parsons, Xuejun
• Application Number:
  US11/435,991
• Publication Number:
  US 20070010011A1
• Time in Patent Office: Days
• US Class Current: 435/366
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: C12N 2500/38 Vitamins
• CPC Class Codes: C12N 2500/44 Thiols, e.g. mercaptoethanol
• CPC Class Codes: C12N 2500/90 Serum-free medium, which may still contain naturally-sourced components
• CPC Class Codes: C12N 2500/98 Xeno-free medium and culture conditions
• CPC Class Codes: C12N 2501/115 Basic fibroblast growth factor (bFGF, FGF-2)
• CPC Class Codes: C12N 2501/33 Insulin together with transferrin C12N2500/25; Insulin-like growth factors C12N2501/105
• CPC Class Codes: C12N 2502/13 connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
• CPC Class Codes: C12N 2503/00 Use of cells in diagnostics
• CPC Class Codes: C12N 2533/52 Fibronectin; Laminin
• CPC Class Codes: C12N 2533/54 Collagen; Gelatin
• CPC Class Codes: C12N 5/0606 Pluripotent embryonic cells, e.g. embryonic stem cells [ES] embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696
• CPC Class Codes: C12N 5/0607 Non-embryonic pluripotent stem cells, e.g. MASC induced pluripotent stem cells C12N5/0696
• CPC Class Codes: G01N 33/5073 Stem cells

Abstract

Stem cells, including mammalian, and particularly primate primordial stem cells (pPSCs) such as human embryonic stem cells (hESCs), hold great promise for restoring cell, tissue, and organ function. However, cultivation of stem cells, particularly undifferentiated hESCs, in serum-free, feeder-free, and conditioned-medium-free conditions remains crucial for large-scale, uniform production of pluripotent cells for cell-based therapies, as well as for controlling conditions for efficiently directing their lineage-specific differentiation. This instant invention is based on the discovery of the formulation of minimal essential components necessary for maintaining the long-term growth of pPSCs, particularly undifferentiated hESCs. Basic fibroblast growth factor (bFGF), insulin, ascorbic acid, and laminin were identified to be both sufficient and necessary for maintaining hESCs in a healthy self-renewing undifferentiated state capable of both prolonged propagation and then directed differentiation. Having discerned these minimal molecular requirements, conditions that would permit the substitution of poorly-characterized and unspecified biological additives and substrates were derived and optimized with entirely defined constituents, providing a “biologics”-free (i.e., animal-, feeder-, serum-, and conditioned-medium-free) system for the efficient long-term cultivation of pPSCs, particularly pluripotent hESCs. Such culture systems allow the derivation and large-scale production of stem cells such as pPSCs, particularly pluripotent hESCs, in optimal yet well-defined biologics-free culture conditions from which they can be efficiently directed towards a lineage-specific differentiated fate in vitro, and thus are important, for instance, in connection with clinical applications based on stem cell therapy and in drug discovery processes.

Claims

1. A defined, isotonic culture medium that is essentially feeder-free and serum-free, comprising:

a. a basal medium;

b. an amount of bFGF sufficient to support growth of substantially undifferentiated mammalian stem cells;

c. an amount of insulin sufficient to support growth of substantially undifferentiated mammalian stem cells; and

d. an amount of ascorbic acid sufficient to support growth of substantially undifferentiated mammalian stem cells.

2. A culture medium according to claim 1 wherein the mammalian stem cells are primate stem cells.

3. A culture medium according to claim 2 wherein the primate stem cells are primate primordial stem cells.

4. A culture medium according to claim 3 wherein the primate primordial stem cells are human primordial stem cells.

5. A culture medium according to claim 4 wherein the human primordial stem cells are human embryonic stem cells.

6. A culture medium according to claim 1 wherein the substantially undifferentiated mammalian stem cells comprise cells that present at least one marker selected from the group consisting of alkaline phosphatase, Oct-4, SSEA-4, Tra-1-60, Tra-1-81, SSEA-1, SSEA-3, Myc, nestin, musashi, vimentin, acetylated histories, p300, Tip60, histone acetyltransferases, and historic deacetylases.

7. A culture medium according to claim 1 wherein the basal medium comprises DMEM, DMEM/F-12, or KO-DMEM, that contains essential amino acids and a carbon source that can be metabolized by the mammalian stem cells.

8. A culture medium according to claim 7 that has a low endotoxin level.

11. A culture medium according to claim 1 wherein the amount of bFGF ranges from about 1 ng/mL to about 20 μ

g/mL.

12. A culture medium according to claim 1 wherein the amount of bFGF is about 20 ng/mL.

13. A culture medium according to claim 1 wherein the amount of insulin ranges from about 1 ng/mL to about 20 mg/mL.

14. A culture medium according to claim 1 wherein the amount of insulin is about 20 μ

g/mL.

15. A culture medium according to claim 1 wherein the amount of ascorbic acid ranges from about 1 ng/mL to about 50 mg/mL.

16. A culture medium according to claim 1 wherein the amount of ascorbic acid is about 50 μ

/mL (microgram/ml).

17. A system for culturing mammalian primordial stem cells in a substantially undifferentiated state, comprising:

a. a defined, isotonic culture medium according to claim 1;

and

b. cell culture vessel includes a substrate comprising a matrix.

18. A system according to claim 17 wherein the mammalian primordial stem cells are primate primordial stem cells.

19. A system according to claim 18 wherein the primate primordial stem cells are human primordial stem cells.

20. A system according to claim 19 wherein the human primordial stem cells are human embryonic stem cells.

21. A system according to claim 18 wherein the matrix is an extracellular matrix.

22. A system according to claim 21 wherein the extracellular matrix is a cell-free matrix prepared from one or more matrix components.

23. A system according to claim 22 wherein the extracellular matrix comprises at least one molecule selected from the group consisting of laminin, fibronectin, collagen, and gelatin.

24. A system according to claim 18 wherein the matrix is provided by a primate feeder cell layer.

25. A system according to claim 24 wherein the primate feeder cell layer is a human feeder cell layer.

26. A system according to claim 25 wherein the human feeder cell layer comprises cells selected from the group consisting of human fibroblast cells, human stromal cells, and cells differentiated from human primordial stem cells.

27. A system according to claim 18 that comprises a plurality of culture vessels for passaging the primate stem cells from one culture vessel to another for continued culturing in a substantially undifferentiated state, wherein a culture vessel used in a subsequent passage comprises the same species of substrate as was used in the culture vessel from which the cells are being passaged.

28. A method of culturing mammalian primordial stem cells in a substantially undifferentiated state, comprising culturing the cells in a culture environment that is essentially free of xenogeneic feeder cells, added conditioned medium from feeder cells, and serum and which comprises a defined, isotonic culture medium according to claim 1.

29. A method according to claim 28 wherein the mammalian primordial stem cells are primate primordial stem cells.

30. A method according to claim 29 wherein said a culture environment comprises at least one component selected from the group consisting bFGF, insulin, ascorbic acid, laminin, or derivatives of such components in an amount sufficient to support substantially undifferentiated growth of primate primordial stem cells.

31. A method according to claim 29 wherein the primate primordial stem cells are human primordial stem cells.

32. A method according to claim 31 wherein the human primordial stem cells are human embryonic stem cells.

33. A method according to claim 31 wherein the primate primordial stem cells are isolated from blastocysts or 1-8 cell stage embryos.

34. A method according to claim 32 wherein the isolation is performed by morphology assessment and selecting as primate primordial stem cells, those cells which present at least one marker selected from the group consisting of Oct-4, SSEA-4, Tra-1-60, Tra-1-81, alkaline phosphatase, SSEA-1, SSEA-3, Sox-2, Myc, acetylated histones, p300, Tip60, histone acetyltransferases (HATs), and histone deacetylases (HDACs).

9. A culture medium according to claim 9 wherein the medium further comprises at least one of the following chemicals selected from the group consisting of non-essential amino acids, anti-oxidants, reducing agents, vitamins, organic compounds, inorganic salts, sodium pyruvate, transferring, and albumins.

10. A culture medium according to claim 9 wherein the reducing agent is β

-mercaptoethanol.

35-48. -48. (canceled)